151 related articles for article (PubMed ID: 23433742)
61. SEOM-GEICO clinical guidelines on endometrial cancer (2021).
Barretina-Ginesta MP; Quindós M; Alarcón JD; Esteban C; Gaba L; Gómez C; Fidalgo JAP; Romero I; Santaballa A; Rubio-Pérez MJ
Clin Transl Oncol; 2022 Apr; 24(4):625-634. PubMed ID: 35312947
[TBL] [Abstract][Full Text] [Related]
62. Endometrial cancer: contemporary insights into our most common gynecologic cancer.
Wenham RM
Cancer Control; 2009 Jan; 16(1):4-5. PubMed ID: 19078923
[No Abstract] [Full Text] [Related]
63. Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine.
Cai Y; Wang B; Xu W; Liu K; Gao Y; Guo C; Chen J; Kamal MA; Yuan C
Curr Med Chem; 2021; 28(42):8755-8781. PubMed ID: 34225603
[TBL] [Abstract][Full Text] [Related]
64. The ErbB Signaling Network and Its Potential Role in Endometrial Cancer.
Androutsopoulos G; Styliara I; Zarogianni E; Lazurko N; Valasoulis G; Michail G; Adonakis G
Epigenomes; 2023 Oct; 7(4):. PubMed ID: 37873809
[TBL] [Abstract][Full Text] [Related]
65. Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities.
Yang FF; Zhao TT; Milaneh S; Zhang C; Xiang DJ; Wang WL
RSC Med Chem; 2024 Jun; 15(6):1828-1848. PubMed ID: 38911148
[TBL] [Abstract][Full Text] [Related]
66. Recent Advances in Endometrial Cancer.
Tran AQ; Gehrig P
F1000Res; 2017; 6():81. PubMed ID: 28184290
[TBL] [Abstract][Full Text] [Related]
67. Adjuvant treatment of endometrial cancer in molecular era: Are we ready to move on?
Paulino E; de Melo AC
Crit Rev Oncol Hematol; 2020 Sep; 153():103016. PubMed ID: 32563900
[TBL] [Abstract][Full Text] [Related]
68. Incorporating molecular profiling into endometrial cancer management requires prospective studies.
Amant F; McCluggage WG; Werner HMJ; Kasius JC; Krakstad C; Pijnenborg J
Int J Gynecol Cancer; 2021 Jun; 31(6):944-945. PubMed ID: 33962995
[No Abstract] [Full Text] [Related]
69. Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives.
Cuccu I; D'Oria O; Sgamba L; De Angelis E; Golia D'Augè T; Turetta C; Di Dio C; Scudo M; Bogani G; Di Donato V; Palaia I; Perniola G; Tomao F; Muzii L; Giannini A
Healthcare (Basel); 2023 Feb; 11(4):. PubMed ID: 36833105
[TBL] [Abstract][Full Text] [Related]
70. Molecular classification of endometrial cancer: entering an era of precision medicine.
Goulder A; Gaillard SL
J Gynecol Oncol; 2022 May; 33(3):e47. PubMed ID: 35443293
[No Abstract] [Full Text] [Related]
71. Lumping and splitting: The need for precision medicine and "personomics" in endometrial cancer.
Reyes-Baez FE; Garzon S; Mariani A
J Gynecol Oncol; 2021 Mar; 32(2):e38. PubMed ID: 33650339
[No Abstract] [Full Text] [Related]
72. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.
Schirmer U; Doberstein K; Rupp AK; Bretz NP; Wuttig D; Kiefel H; Breunig C; Fiegl H; Müller-Holzner E; Zeillinger R; Schuster E; Zeimet AG; Sültmann H; Altevogt P
Oncotarget; 2014 Jan; 5(2):462-72. PubMed ID: 24497324
[TBL] [Abstract][Full Text] [Related]
73. Molecular therapy as a future strategy in endometrial cancer.
Thanapprapasr D; Thanapprapasr K
Asian Pac J Cancer Prev; 2013; 14(6):3419-23. PubMed ID: 23886121
[TBL] [Abstract][Full Text] [Related]
74. Classification of endometrial carcinoma: more than two types.
Murali R; Soslow RA; Weigelt B
Lancet Oncol; 2014 Jun; 15(7):e268-78. PubMed ID: 24872110
[TBL] [Abstract][Full Text] [Related]
75. PDIA6, which is regulated by TRPM2-AS/miR-424-5p axis, promotes endometrial cancer progression via TGF-beta pathway.
Wang P; Zhang T; Jiang N; Wang K; Feng L; Liu T; Yang X
Cell Death Dis; 2023 Dec; 14(12):829. PubMed ID: 38097564
[TBL] [Abstract][Full Text] [Related]
76. lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells.
Chen S; Liang Y; Shen Y; Wang X
Exp Ther Med; 2023 Apr; 25(4):159. PubMed ID: 36911384
[TBL] [Abstract][Full Text] [Related]
77. Alternative splicing of
He S; Cao R; Mao Y; Li N; Wang Y; Ma H; Tian K
J Gynecol Oncol; 2023 May; 34(3):e40. PubMed ID: 36731897
[TBL] [Abstract][Full Text] [Related]
78. Long non-coding RNA SOS1-IT1 promotes endometrial cancer progression by regulating hypoxia signaling pathway.
Liu H; Wan J; Feng Q; Li J; Liu J; Cui S
J Cell Commun Signal; 2022 Jun; 16(2):253-270. PubMed ID: 34637090
[TBL] [Abstract][Full Text] [Related]
79. Role of alternative splicing events in endometrial cancer prognosis.
Liu J; Mi C; Long W; Sun T
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583
[TBL] [Abstract][Full Text] [Related]
80. miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1.
He Y; Ma H; Wang J; Kang Y; Xue Q
Oncol Lett; 2021 May; 21(5):427. PubMed ID: 33850568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
